Related Experiment Video
Updated: Sep 20, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Beyond age and family history: Symptoms as predictors in colorectal cancer screening
Majd Khader1, Rimon Artoul2, Jorge-Shmuel Delgado1
1The Gastroenterology Institute, Assuta Medical Center, Tel Aviv, Israel.
Abstract:
Colorectal cancer (CRC) screening guidelines have prioritized age and clinically relevant family history, yet other clinically relevant parameters remain underutilized. Our study investigates the correlation between CRC-related manifestations and screening performance metrics-polyp detection rate (PDR) and adenoma detection rate (ADR). This cross-sectional retrospective study analyzed 235,781 colonoscopy procedures from eight medical centers in Israel conducted between 2016 and 2022. The dataset comprised the identification and classification of polyps, adenomas, and CRC, in conjunction with patient demographics, clinical background, and particular clinical-laboratory manifestations, including hematochezia, abdominal pain, family history of CRC, fecal occult blood results, and presence of anemia. Our study found significant variations in PDR and ADR based on symptom presence. Patients with hematochezia exhibited a PDR of 36.8% and an ADR of 12.1%, compared to 28.7% and 10.8% in those without it. Furthermore, individuals with occult blood in their feces had a PDR of 48.3% and an ADR of 21.5%, respectively, while those without had rates of 31.6% and 11.0%. In addition, having a family history of CRC is also related to a more significant increase in PDR and ADR of 37.7% and 13.8% compared to patients with no family history of CRC, who had PDR and ADR of 33.3% and 12.2%. Moreover, clinical combinations, including CRC family history with hematochezia or occult blood, had the highest PDR of 62.3% and 58.9%, and ADR of 15% and 20.6%, respectively. Incorporating hematochezia and fecal blood occult tests enhances the effectiveness of the CRC screening.
More Related Videos
07:35Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Related Concept Videos
Assessment of the Rectum and Anus
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Serum Laboratory Studies, Stool Test, Breath Test
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Cancer Prevention
Some...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...